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CD4 T cells play a critical role in mediating adaptive immunity to a variety of pathogens as
well as in tumor immunity. If not adequately regulated, CD4 T cells can be also involved in
autoimmunity, asthma, and allergic responses. DuringTCR activation in a particular cytokine
milieu, naïve CD4T cells may differentiate into one of several lineages ofT helper (Th) cells,
including Th1, Th2, and Th17, as defined by their pattern of cytokine production and func-
tion. IL-1, the prototypic proinflammatory cytokine, has been shown to influence growth
and differentiation of immunocompetent lymphocytes.The differential expression of IL-1RI
on human CD4 T cell subsets confers distinct capacities to acquire specific effector func-
tions. In this review, we summarize the role of IL-1 on CD4T cells, in terms of differentiation,
activation, and maintenance or survival.
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T HELPER CELL SUBSETS
CD4+T helper (Th) lymphocytes represent a heterogeneous pop-
ulation of cells that play an essential role in adaptive immunity.
These cells include effector cells, which are devoted to protection
against pathogens, and regulatory T cells (Tregs), which protect
against effector responses to autoantigens, and also to exogenous
antigens when they become dangerous for the host. The term Th
derived from the observation that these cells were critical for help-
ing B cells to produce antibodies in the primary response (humoral
immunity). CD4+ T cells were also found to be responsible for
the so called cell-mediated immunity, or delayed-type hypersen-
sitivity, which is characterized by reaction involving activation of
macrophages. The distinct protective function of different effector
CD4+ T lymphocytes, enables the best type of response according
to the nature of the invading microorganism. Th1 cells produce
high levels of IFN-γ and are responsible for both phagocyte acti-
vation and the production of opsonizing and complement-fixing
antibodies, thus playing an important role in protection against
intracellular pathogens. Th2 cells produce IL-4, IL-5, IL-9, and
IL-13. Th2 cells, because of their ability to produce IL-4 and IL-
13, can induce IgE class switching by B lymphocytes, enabling in
this way mast cells and basophils sensitization and possible sub-
sequent activation. In addition, IL-5 produced by Th2 cells has
specific activity on differentiation, activation, and recruitment of
eosinophils. Finally, IL-9 has an important role in the proliferation
and accumulation of mast cells and the induction of mucus pro-
duction by cells of the respiratory tract and the gut (1–4). Because
of all the mentioned characteristics, Th2 cells are effective in the
protection against helminthes (5). The more recently discovered
Th17 subset is characterized by the production of IL-17A, IL-17F,
IL-8, IL-21, and IL-22. Th17 cells play a critical role in the recruit-
ment, activation, and migration of neutrophil granulocytes, both
directly, through IL-8 production (6) and indirectly, by inducing,
via IL-17, the production of colony stimulatory factors (CSF) and
CXCL8 (7) in tissue resident cells. Because of their unique ability
to recruit neutrophils, the main protective function of Th17 cells
appears to be the clearance of extracellular pathogens, including
fungi (8, 9). The distinctive features of the various CD4 effec-
tor/regulatory subpopulations are determined largely by the set of
transcription factors they express and the genes they transcribe.
The induction of the distinctive patterns of gene expression is
dependent on the milieu of microenvironmental cytokines during
the antigen-mediated activation of a naïve T cell.
In addition to their protective functions against invading
pathogens, Th1, Th2, and Th17 cells contribute to the develop-
ment of human disorders: Th1 and Th17 cells have been thought
to be involved in the pathogenesis of organ-specific autoimmune
diseases, as well as other chronic inflammatory disorders, such
as Crohn’s disease (CD), psoriasis, and rheumatoid arthritis (RA);
Th2 cells certainly play a central role in the development of allergic
disorders (10–12).
IL-1 FAMILY OF CYTOKINES
Although the original IL-1 family comprised only IL-1α and IL-1β,
the IL-1 family has expanded considerably in the last few years and
nowadays comprises 11 members (IL-1α, IL-1β, IL-1RA, IL-18,
IL-33, IL-36α, IL-36β, IL-36γ, IL-36RA, IL-37, and IL-38) which
have similar gene structure. All these cytokines use heterodimeric
receptors for signaling. IL-1 (α and β) binds to IL-1RI, IL-33 to
T1/ST2 and IL-36 (α,β, and γ) to IL-1Rrp2, and subsequently, they
recruit the same coreceptor IL-1R accessory protein (IL-1RAcP).
IL-18 signals through the IL-18Rα associated to the coreceptor
IL-18Rβ. On receptor binding, all IL-1 family cytokines activate
similar intracellular signals. The signal is initiated with recruit-
ment of the adaptor protein MyD88 to the Toll-IL-1 receptor
(TIR) domain. Several kinases are then phosphorylated, NF-κB
translocates to the nucleus, and the expression of a large portfolio
of inflammatory genes takes place (13) IL-1 receptor antagonist
(IL-1RA) and IL-36RA, act as natural inhibitors for the biologic
activities of IL-1 (α and β) and of IL-36 (α, β, and γ), respectively.
In addition to signaling receptors, also decoy receptors and
inhibitory receptors for IL-1 cytokine family members had been
described. One of these is the IL-1RII that does not signal because
it lacks the TIR cytoplasmic domain. IL-1RII binds IL-1β with
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higher affinity than IL-1RI but does not transduce a signal, act-
ing therefore as a decoy receptor (14). The IL-1RII–IL-1β complex
is able to bind to IL-1RAcP, in this way the decoy receptor also
serves to sequester the accessory receptor from participating in
IL-1 signaling from the IL-1RI. Other receptors characterized by
the ability to deliver inhibitory signals in response to IL-1 family
members are SIGIRR and IL-1RAcPb (15, 16).
Each member of the IL-1 family, IL-1Ra is the unique exception,
is first synthesized as a precursor without a clear signal peptide for
processing and secretion, and none are found in the Golgi. IL-1α
and IL-33 are similar in that their precursor forms can bind to their
respective receptor and trigger signal transduction. The precursor
forms of IL-18 and IL-1β do not bind their respective receptors, are
not active, and require cleavage by either intracellular caspase-1 or
extracellular neutrophilic proteases (17).
Since the discovery of this family of cytokines their “immunos-
timulant activity” was evident, but wasn’t that clear on which and
how this cytokine could interact on different T lymphocytes. The
present review will focalize exclusively on two members of the IL-
1 family of cytokines, IL-1α and IL-1β, and it will discuss, on the
basis of the last 30 years literature, their involvement in the differ-
entiation, activation, and maintenance or survival of the different
Th cell subsets.
The IL-1α precursor is produced constitutively in all epithe-
lial cells and fibroblasts and can be also found on the surface
of several cells, particularly on monocytes and B lymphocytes.
The primary sources of IL-1β are the blood monocytes, tissue
macrophages, and dendritic cells; B lymphocytes and NK cells also
produce IL-1β (18).
IL-1 AND THE TH2 IMMUNE RESPONSE
In the 80s the first studies taking in account the direct effects of
the prototypic proinflammatory cytokine, IL-1, on T lymphocytes
were published (19–21). These studies indicated IL-1 as a cytokines
possibly influencing growth and differentiation of immunocom-
petent lymphocytes. IL-1 costimulatory role for T cells was at that
time attributed to two complimentary effects: (1) IL-1 can enhance
transcription and secretion of the T cell growth factor IL-2; (2) IL-
1 stimulates the expression of the membrane receptors for IL-2.
The combination of these complimentary effects of IL-1 on T cells
could explain its T-cell stimulating function. In 1988, Lichtman
and colleagues (20) were the first to evaluate IL-1α costimulatory
function on, at that time recently discovered, murine Th1 and Th2
cells. In this study, the authors demonstrated that only Th2 cells
express high affinity receptors for IL-1 and that, accordingly, only
this cell subset proliferate in response to IL-1α, whereas Th1 cells
do not.
Few years later, Taylor-Robinson and colleagues (22), exam-
ining the expression of selected interleukin receptors by cloned
CD4+ T cells specific for the murine malaria parasite Plasmodium
chabaudi representative of the Th1 and Th2 subsets, found that
while IL-1RI was constantly expressed by Th2 clones, its expres-
sion by the Th1 clones was either negligible or undetectable. Since
then, the scientific community assumed that just the Th2 cell sub-
set expresses IL-1RI, but lacking to confirm this data on human
cells. Considering the pathogenic role of Th2 cells in allergic dis-
eases, IL-1 activity was therefore investigated in several murine
models of allergy. Nakae and colleagues (23) demonstrated that
the ovalbumin-induced airway hypersensitivity response (AHR)
in IL-1α/β-double deficient mice was significantly reduced when
compared to wild type mice, whereas the response seen in IL-
1RA-deficient mice was profoundly exacerbated, suggesting that
IL-1 is required for Th2 cell activation during AHR. Accord-
ingly, the authors showed that ovalbumin-specific IL-4 and IL-5
production by T cells, and IgG1 and IgE production by B cells in IL-
1α/β-double deficient mice were markedly reduced compared with
these responses in wild type mice. Similar results were obtained
by Schmitz and colleagues (24) that investigated the role of IL-
1 in models of allergic asthma using IL-1R1-deficient mice. The
authors showed that in a model of mild asthma, based on repeated
sensitization of mice with low doses of ovalbumin in the absence of
any adjuvant, the pulmonary eosinophilic inflammation, the gob-
let cell hyperplasia, as well as antibody responses including IgG,
IgE, and IgA were strongly reduced in IL-1R1-deficient as com-
pared to wild type mice. In contrast, sensitization of mice in the
presence of alum adjuvant, a more severe asthma model, rendered
the IL-1 pathway dispensable for the development of pulmonary
allergic Th2 responses. The role of IL-1 in sustaining the Th2
immune responses comes also from animal models of parasites
infestation. Helmby and Grencis (25) showed that Th2 response-
associated resistance to gastrointestinal nematode Trichuris muris
is mediated was dependent on the presence of IL-1α and IL-1β.
Indeed, they demonstrated that both IL-1α- and IL-1β-deficient
mice were susceptible to chronic Trichuris muris infection and that
the inability to eliminate the worms was associated with a defect in
the development of a Th2 response in the mesenteric lymph nodes.
Opposite data were obtained by Satoskar and colleagues (26) that
found significantly increased IL-4 and IL-10 production by lymph
node cells from Leishmania major infected IL-1RI-deficient mice
when compared to wild type mice.
These findings are contradictory to the one showed by Helmby
and Grencis, possibly because of differences in the type of
cytokine/receptor KO utilized, the choice of experimental model,
as well as the genetic background of the host.
The first description of IL-1RI expression and modulation on
human T cells, however without distinguishing on which particu-
lar subsets, was made by Shirakawa and colleagues (21). Few years
later Manetti and colleagues (27) analyzed the effects exerted by IL-
1α on the growth and differentiation of human Th1 and Th2 cells.
In this study, the authors showed that neither IL-1αnor the IL-1RA
had detectable activity toward the antigen- or anti-CD3 antibody-
induced proliferative response of already established Th1 or Th2
clones. However, allergen-specific T-cell lines, derived in the pres-
ence of anti-IL-1α Ab or IL-1RA, exhibited reduced and increased
ability to produce IL-4 and IFN-γ, respectively. These data sug-
gested that IL-1α was not required for the growth of already
established human Th1 or Th2 clones, but it played a critical role
in the development of Th2 cells, whereas Th1 development was
unaffected. In light of the above mentioned data, the lack of an
effect, described by Manetti, in terms of proliferative response to
IL-1α on already established human Th2 cells and the reduction
in the Th2 polarization in IL-1α neutralizing conditions, could be
interpreted today as an indirect effect on non-Th2 subsets that are
expanded in the presence of IL-1α (27).
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The first data relative to the expression of IL-1RI on a particular
Th cell subsets came out only in 2010. Indeed, Cosmi and col-
leagues (28) demonstrated the lack of IL-1-RI mRNA on human
established Th2 clones, while Wang and colleagues (29) observed
a slight membrane expression of the receptor on freshly enriched
human CRTH2 positive cells, being CRTH2 a surface molecule
selectively expressed by human Th2 cells (30, 31).
In any case neither Cosmi nor Wang analyzed the ability of the
human Th2 cells to respond to IL-1, i.e., monitoring the activation
signal transduction molecules downstream the IL-1RI, therefore
it is not known if the receptor has functional activity.
Since the activity of IL-1 on human Th2 cells is not unequivo-
cally established, caution is needed in considering this cytokine as
potential new therapeutic target for human bronchial asthma as
some studies suggest (32).
BOTH MICE AND HUMANS TH17 EXPRESS IL-1RI AND ARE
MODULATED BY ITS SIGNALING
For the in vitro differentiation of naïve T cell into Th17 cells in the
mouse, the scientific community was fairly unanimous in defining
TGF-β and IL-6, as the key cytokines. Yet in 2006 Veldhoen and
colleagues (33) described a synergistic role of IL-1β and TNF-α
in the Th17 differentiation initiated by TGFβ and IL-6 and in the
same year Sutton and colleagues (34) described a lower induction
of Th17 cells in IL-1RI-deficient mice, than in wild type mice and
also a resistance to experimental autoimmune encephalomyelitis
(EAE). Interestingly, in models of autoimmune diseases, such as
EAE and collagen-induced arthritis (CIA), the induction of the
Th17 cells require the presence of a mixture of killed Mycobac-
terium tuberculosis, that has been recently discovered to induce, via
dectin-1 and TLR4, the release of IL-1β (35). Therefore it’s possi-
ble to speculate that IL-1β plays a pivotal role in Th17 induction.
This hypothesis is confirmed observing mice deficient in caspase1-
enzyme that cleaves IL-1β precursor into a mature form-, where
EAE is markedly attenuated. On the other hand when IL-1β activ-
ity is unopposed, like in IL-1RA knot-out mice (C57BL/6J), causes
autoimmunity and arthritis that closely resembled RA in humans
(36). These data have been confirmed, observing that mice specifi-
cally deficient in endogenous IL-1RA developed an increased Th17
response, and CIA appears to be because of unrestrained IL-1
activity (37, 38), which may in turn, contribute to a more severe
form of CIA. In keeping with these observations Coccia and col-
leagues (39) showed that IL-1β promotes intestinal inflammation
by augmenting the recruitment of granulocytes and the accumula-
tion and activation of innate lymphoid cells (ILCs) in a model of in
Helicobacter hepaticus-triggered intestinal inflammation. In par-
ticular, the observation that synergistic interactions between IL-1β
and IL-23 sustain innate and adaptive inflammatory responses in
the gut, promoting intestinal pathology, suggests that targeting IL-
1β may represent a useful therapeutic approach in IBD. To further
support the possibility of IL-1β play significant role not only in
the induction of Th17 phenotype, but also in their expansion and
homeostatic maintenance, Sutton and colleagues reported that IL-
1β can promote Th17 expansion and cytokine production in vitro
even in the absence of TCR stimulation. The mechanisms under-
lying these in vivo phenomena became more clear since it has been
described IL-1RI expression first on IL-17+CD4+ T cells of SKG
mice (that spontaneously develop arthritis) (40), and later on, by
the demonstration that IL-1 signaling is required for the upregu-
lation of IRF4 and RORC (two fundamental Th17 transcription
factors) during the early Th17 lineage programing and to sustain
its differentiation (41).
When the differentiation process, from naïve to effector cells,
was analyzed in humans, a number of evidence showed soon that
a predominant role was led by IL-1β, alone or in combination
with other cytokines. Annunziato and colleagues (42) described
the expression of IL-1RI on Th17 cell clones derived from periph-
eral blood (PB) and gut specimens of Crohn’s affected patients,
and, accordingly, Acosta-Rodriguez and colleagues (43) was able
to induce a Th17 phenotype by culturing naïve T cells in pres-
ence of IL-1β and IL-6. In particular, IL-1β was sufficient to
induce the expression of RORC and production of both IL-17
and IFN-γ. Cosmi and colleagues reported that all humans IL-
17-producing cells originate from CD161+ naïve CD4+ T cells
of umbilical cord blood, as well as of the postnatal thymus, in
response to the combined activity of IL-1β and IL-23. Confirma-
tion that IL-1β is important in the differentiation of Th17 cells
comes from studies conducted on the CD161 positive fraction of
naïve CD3+CD4+ cell from the thymus as well from the cord
blood of newborns where the combination of IL-1β and IL-23
allows the Th17 polarization (44, 45).
These data were recently confirmed by Lee and colleagues (46)
who, demonstrated the upregulation of IL-1RI on naïve cord blood
CD4+ T cell after exposure to common γ-chain cytokines (IL-7,
IL-15) plus TGF-β and establishing that such condition promote
the differentiation into Th17 cells upon TCR triggering and IL-1β
stimulation, which is enhanced by IL-23 and blocked by IL-1RA.
The same upregulation of IL-1RI was described by Raffin and
colleagues (47) on PB naïve CD4+ T cell in the presence of the
combination of IL-2, IL-1β, IL-23, and TGF-β.
In human disease, several clinical studies support a role for IL-
1β secreted by colon lamina propria monocytes in disease activity
during IBD. IL-1β levels in the colon during active phase of IBD
correlated with disease activity and high levels of IL-1β were asso-
ciated with active lesions (48), suggesting an important role of this
cytokine in promoting localized inflammation.
A human example of IL-1β dysregulation is the heterozygous
mutation of NLRP3 gene (encoding for the inflammasome com-
ponent, cryopyrin) that leads to an abnormal secretion of IL-1β by
monocytes, leading to different clinical inflammatory manifesta-
tions, but all hampered by inhibition of IL-1β. Indeed Lasiglie
(49) analyzing 11 patients carrying this mutation (Cryopyrin-
associated periodic syndromes, CAPS) observed a skewed Th17
phenotype in PB lymphocytes, as well as an increased production
of IL-1β and IL-23 by monocyte-derived dendritic cells. The anti-
IL-1β treatment in vivo reduce the secretion of IL-1β by monocytes
and both IL-1β and IL-23 by monocyte-derived dendritic cells
in vitro. The observation that IL-1RA treatment leads to a down
modulation of IL-23 in PBMC of celiac patients may support the
hypothesis that the over expression of IL-23 in CAPS patients is
actually related to an IL-1β dependent mechanism, likely associ-
ated to the activation of the inflammasome (50). The second arm
of “IL-1 system” has been enlighted in 2009 with the identifica-
tion (51) of the cause of a human autoinflammatory syndrome
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of skin and bone in a homozygous truncating mutations in the
IL-1RN gene that leads to the lack of secretion of this receptor
antagonist (IL-1RA), and as a consequence in an unopposed IL-1
signaling. Increased number of IL-17 secreting cells was found in
biopsy samples of inflamed skin from patients with deficiency of
the IL-1RA (DIRA patients); as expected treatment with Anakinra,
a recombinant IL-1RA, leaded to symptoms remission.
We can conclude that many evidence in mice and humans
support the concept that IL-1β, acting concurrently with other
cytokines, is a key cytokine in the early phases of Th17 develop-
ment, acting through its specific receptor expressed already by the
naïve CD4+ Th17’s precursor.
Moreover, even if IL-1β plays an important role in combating
the invading pathogen as part of the innate immune response, its
dysregulation is responsible for a number of autoinflammatory
disorders in which Th17 cells are involved. As a consequence, its
inhibition has proved therapeutically beneficial in the treatment
of a spectrum of serious, yet relatively rare, heritable patholo-
gies. This raises the possibility that anti-IL-1 therapeutics may
have broader applications than previously believed, and may be
utilized across diverse disease states that are linked insidiously
through heightened inflammasome activity.
TH1 “NON-CLASSIC” HUMAN T CELL EXPRESS IL-1RI: A NEW
POINT OF VIEW
Because of the scientific community had assumed the absence
of IL-1RI expression by Th1 cells, very few works subsequently
investigated the possible expression and function of this recep-
tor on Th cell subset. Ben-Sasson and colleagues (52) were the
first that described an activation effect of IL-1β on Th1 cells in
a mouse model. The first data on human Th1 cells came from
the study of Cosmi and colleagues mentioned before (44). In
this study, the authors demonstrated that the combination of IL-
1β and IL-23 was able to induce the development of Th17 cells
in CD4+CD161+ cells, and also the Th1 phenotype, in both
CD4+CD161+ and CD4+CD161− cell fractions. This observa-
tion leads the authors to hypothesize that also Th1 cells able to
respond to IL-1β could exist. In keeping with this hypothesis, it
has been recently found (53) that the CD4+CD161+ clones and
inflamed tissue derived cells able to produce IFN-γ expressed IL-
1RI mRNA. Interestingly, in the synovial fluid of JIA patients,
the CD4+CD161+ IFN-γ-producing cells showed higher IL-1RI
mRNA expression when compared to the CD4+CD161− coun-
terpart (54). Of note, in this paper Cosmi and colleagues has
highlighted the plasticity of Th17 cells showing that Th1 clones,
expressing CD161 (named as “non-classic Th1 cells”), derive from
an in vivo shifting of Th17 cells toward a Th1 phenotype. Interest-
ingly, the authors found significantly increased levels of IL-12 in
the SF of JIA patients and that Th17 cells from the PB of healthy
children could be induced to shift to Th1 cells when cultured
in vitro in the presence of JIA SF. More importantly, this effect was
completely reversed by a neutralizing anti-IL-12 mAb, strongly
suggesting that the shifting of Th17 cells toward the Th1 phenotype
was related mainly to the activity of IL-12 present in the SF.
The late plasticity of Th17 cells to Th1 cells has been recently
confirmed also in mice, where it has been found that IL-12, or
the prolonged exposure to IL-23, is able to polarize Th17 cells
toward the Th1 phenotype (55). Furthermore, similar results were
recently reported by Nistala and colleagues (56), that showed Th17
plasticity to Th1 to be driven by the inflammatory environment in
human autoimmune arthritis. Finally, very recently, the instability
of the Th17 phenotype has been definitively demonstrated, at a
genetic level, in mice (57).
These new data leads us to argue that up to now the scientific
community overlooked this population of “non-classic Th1” cells
expressing CD161 and IL-1RI (53). As mentioned before in this
review many animal models of autoimmune disorders demon-
strate the pivotal role of IL-1 in the pathogenesis of the disease
and its relationship to Th17, but failed to look at the Th1 cells that
could be affected by a lack of IL-1 signaling. In this context, the
presence, and sometimes the prevalence, of Th1 cells in the inflam-
matory tissues have been interpreted as a protective, rather than
proinflammatory, function. In humans many autoinflammatory
disorders are treated blocking IL-1β [i.e., Familial Mediterranean
fever (FMF), Pyogenic arthritis, pyoderma gangrenosum, acne
(PAPA), CAPS, Hyper IgD syndrome (HIDS), Adult and juve-
nile Still disease Schnitzler syndrome, TNF receptor-associated
periodic syndrome (TRAPS), Blau syndrome; Sweet syndrome,
Deficiency in IL-1 receptor antagonist (DIRA)]. Initially, Anakinra
(IL-1RA) was used to treat several chronic inflammatory diseases,
today, these diseases are also successfully treated with neutraliza-
tion by human anti-IL-1β monoclonal Abs. It’s time to speculate
that the improvements observed during these treatments are not
only due to the general anti-inflammatory effects and to the
reduction in terms of production, survival and differentiation
of Th17 cells, but also on the activity on Th1 effector cells in
particular Th1 expressing IL-1RI probably derived from a Th17
phenotype (42, 53).
CONCLUDING REMARKS
Since the discovery of the lack of IL-1RI on murine Th1 cells, most
of the studies focused their attention to in vivo animal models of
Th2 related diseases. Different models of mice either deficient for
IL-1RI or for IL-1α/IL-1β were analyzed to verify the effects in
the Th2 response; most of the studies agree with the idea that
both cytokines promote proliferation and differentiation of Th2
cells in vitro and in vivo, but some other found no effects or
even the opposite. The contradictory findings could be related
to the different animal models used, the different protocol of dis-
ease induction, the different genetic background; furthermore the
analysis conducted on ex vivo bulk cultures may induce to overesti-
mate some observations that are actually side or indirect effects. As
most of the conclusions made on the basis of animal models could
have an impact in clinical practice, we would have expected to find
many papers confirming or disproving these data on human cells.
Surprisingly very few studies focused on the effects of IL-1α either
IL-1β in human Th2 cells, and the findings do not enlighten if
human Th2 cells express a functional IL-1RI and therefore can be
modulated by these cytokines.
Conversely, as we look to the relationship between IL-1β and
Th17, human’s studies and animal models supported both the con-
cept that IL-1β has a fundamental role in Th17 modulation. Two
genetic human diseases carrying an impairment in IL-1β either
in the expression or in its regulation and showing a skewed Th17
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FIGURE 1 | IL-1β and IL-23 induce the differentiation of human CD161+ precursor toward both theTh17 and the non-classicTh1 phenotype. IL-1 β
together with IL-23 acts on human CD4+CD161+ precursor to induce Th17 and non-classic Th1 effector cells. Th17 can shift toward a non-classic Th1 phenotype
in the presence of IL-12.
phenotype, is for sure of great confirmation of in vitro/ex vivo data.
The in vitro assays clarify that IL-1β is able to induce those tran-
scription factors necessary for Th17 development, as soon as its
own receptor is upregulated in naïve T cells upon TCR triggering
in the presence of γ-chain cytokines. The cooperation with other
cytokines, i.e., IL-23, IL-6, IL-21 leads to the differentiation and the
stabilization of the phenotype (39, 43, 58, 59); IL-1RI expression
is long lasting, maintained on effector Th17 cells and its signaling
is probably responsible for their survival during inflammation.
The recent discovery of Th17 plasticity toward a Th1 phenotype
in the presence of an inflammatory environment is driving the
scientific community to focus attention also to those Th1 highly
present in many autoimmune diseases that have been so far con-
sidered protective rather than pathogenic; it is intriguing, that also
a sub population of human Th1 cells expressing CD161 and deriv-
ing from Th17 (named “Th1 non-classic”) do express IL-1RI and
most likely respond to IL-1β (Figure 1). It is therefore likely that the
therapeutically approaches were the IL-1β activity is blocked, like
in JIA patients, are effective because acting on these Th1 CD161+
IL-1RI cells whose number correlate with some parameter disease.
Moreover other autoimmune diseases, where Th1 CD161+ IL-1RI
cells were increased, could benefit of an anti-IL-1 treatment.
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